Strong first-half growth, then a bid-rigging charge clouds the outlook
First-half profit and revenue jumped about 50% Shengnuo Bio's first-half net profit rose 52% to 135 million yuan and revenue rose 50.3% to 507 million yuan, with second-quarter growth even faster. This shows the peptide drug business is expanding strongly, which supports a higher share price.
The half-year report is the core new fundamental event that confirms rapid earnings growth.
Profit growth was backed by real cash and steady margins Operating cash flow rose 6.8% to 87 million yuan, gross margin stayed high at 58.7%, and return on equity was 11.8%. Cash-backed profit and healthy margins make the growth more believable and reduce the risk of a sharp negative reaction.
It explains why the earnings growth is credible and not just accounting noise.
Subsidiary and controller indicted for bid-rigging A wholly owned subsidiary and the actual controller were indicted for colluding in national drug procurement bidding. The company already set aside 10.98 million yuan and expects fines that could cut future profit, and the case creates uncertainty about future sales of its finished drugs.
This is the main new risk that can push the share price down and offset the strong earnings.
Early profit forecast set expectations for strong growth In July the company guided first-half net profit to rise 43% to 65% year on year. That early signal prepared investors for the strong result and helped support the stock before the full report arrived.
It shows the market was already told growth would be strong, which frames the later report.